KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Accumulated Depreciation (2018 - 2023)

Vir Biotechnology (VIR) has disclosed Accumulated Depreciation for 6 consecutive years, with $26.2 million as the latest value for Q1 2023.

  • Quarterly Accumulated Depreciation rose 65.06% to $26.2 million in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $26.2 million through Mar 2023, up 65.06% year-over-year, with the annual reading at $20.7 million for FY2022, 43.13% up from the prior year.
  • Accumulated Depreciation hit $26.2 million in Q1 2023 for Vir Biotechnology, up from $20.7 million in the prior quarter.
  • In the past five years, Accumulated Depreciation ranged from a high of $26.2 million in Q1 2023 to a low of $4.2 million in Q3 2019.
  • Historically, Accumulated Depreciation has averaged $12.5 million across 5 years, with a median of $11.8 million in 2021.
  • Biggest five-year swings in Accumulated Depreciation: soared 181.59% in 2019 and later soared 43.13% in 2022.
  • Year by year, Accumulated Depreciation stood at $4.8 million in 2019, then surged by 91.06% to $9.2 million in 2020, then skyrocketed by 56.98% to $14.5 million in 2021, then surged by 43.13% to $20.7 million in 2022, then rose by 26.54% to $26.2 million in 2023.
  • Business Quant data shows Accumulated Depreciation for VIR at $26.2 million in Q1 2023, $20.7 million in Q4 2022, and $18.9 million in Q3 2022.